Approaches in the study of ganglioside metabolism.

G. Tettamanti, R. Ghidoni, S. Sonnino, V. Chigorno, B. Venerando, A. Giuliani, A. Fiorilli

Research output: Contribution to journalArticle

Abstract

Ganglioside GM1, 3H-labeled in the sphingosine or terminal galactose moiety was injected into mice and its metabolic fate in the liver was followed. After administration of sphingosine-labeled GM1 all major liver gangliosides (GM3, GM2, GM1, GD1a-NeuAc, NeuG1) became radioactive, the radioactivity residing in all cases on the sphingosine moiety. The specific radioactivity was highest on GM1, followed by GM2, GM3 and GD1a-NeuAc, NeuG1. Several neutral glycosphingolipids and sphingomyelin were also formed. After administration of galactose-labelled GM1 the only radioactive gangliosides present in the liver were GM1 and GD1a-NeuAc, NeuG1, both carrying the radioactivity on the terminal galactose residue, with no formation of labelled neutral glycosphingolipids. Subcellular studies gave clear evidence that GM1, after being taken up by the liver, was mainly degraded to GM2, GM3 and neutral glycosphingolipids at the level of lysosomes. A part of it was sialylated to more complex gangliosides and some of its metabolic by-products were used for the biosynthesis of other sphingolipid species, likely at the level of the Golgi apparatus. All this suggests that exogenous GM1 is introduced in the metabolic routes of endogenous gangliosides and of other sphingolipids, which are operating in the liver.

Original languageEnglish
Pages (from-to)273-284
Number of pages12
JournalAdvances in Experimental Medicine and Biology
Volume174
Publication statusPublished - 1984

Fingerprint

Gangliosides
Metabolism
Liver
Neutral Glycosphingolipids
Sphingosine
Radioactivity
Galactose
Sphingolipids
G(M2) Ganglioside
G(M3) Ganglioside
G(M1) Ganglioside
Sphingomyelins
Biosynthesis
Golgi Apparatus
Lysosomes
Byproducts

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tettamanti, G., Ghidoni, R., Sonnino, S., Chigorno, V., Venerando, B., Giuliani, A., & Fiorilli, A. (1984). Approaches in the study of ganglioside metabolism. Advances in Experimental Medicine and Biology, 174, 273-284.

Approaches in the study of ganglioside metabolism. / Tettamanti, G.; Ghidoni, R.; Sonnino, S.; Chigorno, V.; Venerando, B.; Giuliani, A.; Fiorilli, A.

In: Advances in Experimental Medicine and Biology, Vol. 174, 1984, p. 273-284.

Research output: Contribution to journalArticle

Tettamanti, G, Ghidoni, R, Sonnino, S, Chigorno, V, Venerando, B, Giuliani, A & Fiorilli, A 1984, 'Approaches in the study of ganglioside metabolism.', Advances in Experimental Medicine and Biology, vol. 174, pp. 273-284.
Tettamanti G, Ghidoni R, Sonnino S, Chigorno V, Venerando B, Giuliani A et al. Approaches in the study of ganglioside metabolism. Advances in Experimental Medicine and Biology. 1984;174:273-284.
Tettamanti, G. ; Ghidoni, R. ; Sonnino, S. ; Chigorno, V. ; Venerando, B. ; Giuliani, A. ; Fiorilli, A. / Approaches in the study of ganglioside metabolism. In: Advances in Experimental Medicine and Biology. 1984 ; Vol. 174. pp. 273-284.
@article{3c640c4e77a64391a2d53446c2c4172a,
title = "Approaches in the study of ganglioside metabolism.",
abstract = "Ganglioside GM1, 3H-labeled in the sphingosine or terminal galactose moiety was injected into mice and its metabolic fate in the liver was followed. After administration of sphingosine-labeled GM1 all major liver gangliosides (GM3, GM2, GM1, GD1a-NeuAc, NeuG1) became radioactive, the radioactivity residing in all cases on the sphingosine moiety. The specific radioactivity was highest on GM1, followed by GM2, GM3 and GD1a-NeuAc, NeuG1. Several neutral glycosphingolipids and sphingomyelin were also formed. After administration of galactose-labelled GM1 the only radioactive gangliosides present in the liver were GM1 and GD1a-NeuAc, NeuG1, both carrying the radioactivity on the terminal galactose residue, with no formation of labelled neutral glycosphingolipids. Subcellular studies gave clear evidence that GM1, after being taken up by the liver, was mainly degraded to GM2, GM3 and neutral glycosphingolipids at the level of lysosomes. A part of it was sialylated to more complex gangliosides and some of its metabolic by-products were used for the biosynthesis of other sphingolipid species, likely at the level of the Golgi apparatus. All this suggests that exogenous GM1 is introduced in the metabolic routes of endogenous gangliosides and of other sphingolipids, which are operating in the liver.",
author = "G. Tettamanti and R. Ghidoni and S. Sonnino and V. Chigorno and B. Venerando and A. Giuliani and A. Fiorilli",
year = "1984",
language = "English",
volume = "174",
pages = "273--284",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Approaches in the study of ganglioside metabolism.

AU - Tettamanti, G.

AU - Ghidoni, R.

AU - Sonnino, S.

AU - Chigorno, V.

AU - Venerando, B.

AU - Giuliani, A.

AU - Fiorilli, A.

PY - 1984

Y1 - 1984

N2 - Ganglioside GM1, 3H-labeled in the sphingosine or terminal galactose moiety was injected into mice and its metabolic fate in the liver was followed. After administration of sphingosine-labeled GM1 all major liver gangliosides (GM3, GM2, GM1, GD1a-NeuAc, NeuG1) became radioactive, the radioactivity residing in all cases on the sphingosine moiety. The specific radioactivity was highest on GM1, followed by GM2, GM3 and GD1a-NeuAc, NeuG1. Several neutral glycosphingolipids and sphingomyelin were also formed. After administration of galactose-labelled GM1 the only radioactive gangliosides present in the liver were GM1 and GD1a-NeuAc, NeuG1, both carrying the radioactivity on the terminal galactose residue, with no formation of labelled neutral glycosphingolipids. Subcellular studies gave clear evidence that GM1, after being taken up by the liver, was mainly degraded to GM2, GM3 and neutral glycosphingolipids at the level of lysosomes. A part of it was sialylated to more complex gangliosides and some of its metabolic by-products were used for the biosynthesis of other sphingolipid species, likely at the level of the Golgi apparatus. All this suggests that exogenous GM1 is introduced in the metabolic routes of endogenous gangliosides and of other sphingolipids, which are operating in the liver.

AB - Ganglioside GM1, 3H-labeled in the sphingosine or terminal galactose moiety was injected into mice and its metabolic fate in the liver was followed. After administration of sphingosine-labeled GM1 all major liver gangliosides (GM3, GM2, GM1, GD1a-NeuAc, NeuG1) became radioactive, the radioactivity residing in all cases on the sphingosine moiety. The specific radioactivity was highest on GM1, followed by GM2, GM3 and GD1a-NeuAc, NeuG1. Several neutral glycosphingolipids and sphingomyelin were also formed. After administration of galactose-labelled GM1 the only radioactive gangliosides present in the liver were GM1 and GD1a-NeuAc, NeuG1, both carrying the radioactivity on the terminal galactose residue, with no formation of labelled neutral glycosphingolipids. Subcellular studies gave clear evidence that GM1, after being taken up by the liver, was mainly degraded to GM2, GM3 and neutral glycosphingolipids at the level of lysosomes. A part of it was sialylated to more complex gangliosides and some of its metabolic by-products were used for the biosynthesis of other sphingolipid species, likely at the level of the Golgi apparatus. All this suggests that exogenous GM1 is introduced in the metabolic routes of endogenous gangliosides and of other sphingolipids, which are operating in the liver.

UR - http://www.scopus.com/inward/record.url?scp=0021317879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021317879&partnerID=8YFLogxK

M3 - Article

C2 - 6377848

AN - SCOPUS:0021317879

VL - 174

SP - 273

EP - 284

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -